Page 150 - MI-2-4

Microbes & Immunity Glioblastoma therapy: Immunotherapy and inhibitors

Ertel C. Human tumor cell modification by virus infection: 2008;105(13):5213-5218.
An efficient and safe way to produce cancer vaccine with doi: 10.1073/pnas.0801279105
pleiotropic immune stimulatory properties when using
Newcastle disease virus. Gene Ther. 1999;6(1):63-73. 84. Maher EA, Brennan C, Wen PY, et al. Marked genomic
differences characterize primary and secondary
doi: 10.1038/sj.gt.3300787
glioblastoma subtypes and identify two distinct molecular
74. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic and clinical secondary glioblastoma entities. Cancer Res.
escape after prolonged progression-free survival with 2006;66(23):11502-11513.
epidermal growth factor receptor variant III peptide doi: 10.1158/0008-5472.CAN-06-2072
vaccination in patients with newly diagnosed glioblastoma.
J Clin Oncol. 2010;28(31):4722-4729. 85. Mischel PS, Nelson SF, Cloughesy TF. Molecular analysis
of glioblastoma: Pathway profiling and its implications for
doi: 10.1200/JCO.2010.28.6963
patient therapy. Cancer Biol Ther. 2003;2(3):242-247.
75. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal doi: 10.4161/cbt.2.3.369
growth factor ligand-independent, unregulated, cell-
transforming potential of a naturally occurring human mutant 86. Dubois LG, Campanati L, Righy C, et al. Gliomas and
EGFRvIII gene. Cell Growth Differ. 1995;6(10):1251-1259. the vascular fragility of the blood brain barrier. Front Cell
Neurosci. 2014;8:418.
76. Boockvar JA, Kapitonov D, Kapoor G, et al. Constitutive
EGFR signaling confers a motile phenotype to neural stem doi: 10.3389/fncel.2014.00418
cells. Mol Cell Neurosci. 2003;24(4):1116-1130. 87. Monteiro AR, Hill R, Pilkington GJ, Madureira PA. The role
doi: 10.1016/j.mcn.2003.09.011 of hypoxia in glioblastoma invasion. Cells. 2017;6(4):45.
77. Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, doi: 10.3390/cells6040045
Bigner DD. Receptor dimerization is not a factor in the 88. Urbańska K, Sokołowska J, Szmidt M, Sysa P. Glioblastoma
signalling activity of a transforming variant epidermal growth multiforme - an overview. Contemp Oncol (Pozn).
factor receptor (EGFRvIII). Biochem J. 1997;324(Pt 3): 2014;18(5):307-312.
855-861.
doi: 10.5114/wo.2014.40559
doi: 10.1042/bj3240855
89. Thakur A, Faujdar C, Sharma R, et al. Glioblastoma: Current
78. Heimberger AB, Hlatky R, Suki D, et al. Prognostic status, emerging targets, and recent advances. J Med Chem.
effect of epidermal growth factor receptor and EGFRvIII 2022;65(13):8596-8685.
in glioblastoma multiforme patients. Clin Cancer Res.
2005;11(4):1462-1466. doi: 10.1021/acs.jmedchem.1c01946
90. Arévalo ÁST, Erices JI, Uribe DA, et al. Current therapeutic
doi: 10.1158/1078-0432.CCR-04-1737
alternatives and new perspectives in glioblastoma
79. Hottinger AF, Stupp R, Homicsko K. Standards of care multiforme. Curr Med Chem. 2017;24(25):2781-2795.
and novel approaches in the management of glioblastoma
multiforme. Chin J Cancer. 2014;33(1):32-39. doi: 10.2174/0929867324666170303122241
91. Fernandes GFD, Fernandes BC, Valente V, Dos Santos JL.
doi: 10.5732/cjc.013.10207
Recent advances in the discovery of small molecules
80. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy targeting glioblastoma. Eur J Med Chem. 2019;164:8-26.
plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 2005;352(10):987-996. doi: 10.1016/j.ejmech.2018.12.033
92. Khaddour K, Johanns TM, Ansstas G. The landscape of novel
doi: 10.1056/NEJMoa043330
therapeutics and challenges in glioblastoma multiforme:
81. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of Contemporary state and future directions. Pharmaceuticals
migration: Invasion of malignant gliomas and implications (Basel). 2020;13(11):389.
for treatment. J Clin Oncol. 2003;21(8):1624-1636.
doi: 10.3390/ph13110389
doi: 10.1200/JCO.2003.05.063
93. Zahonero C, Aguilera P, Ramírez-Castillejo C, et al.
82. Tzeng SY, Green JJ. Therapeutic nanomedicine for brain Preclinical test of dacomitinib, an irreversible EGFR
cancer. Ther Deliv. 2013;4(6):687-704. inhibitor, confirms its effectiveness for glioblastoma. Mol
Cancer Ther. 2015;14(7):1548-1558.
doi: 10.4155/tde.13.38
83. Diehn M, Nardini C, Wang DS, et al. Identification doi: 10.1158/1535-7163.MCT-14-0736
of noninvasive imaging surrogates for brain tumor 94. Hamed HA, Tavallai S, Grant S, Poklepovic A, Dent P.
gene-expression modules. Proc Natl Acad Sci U S A. Sorafenib/regorafenib and lapatinib interact to kill CNS

Volume 2 Issue 4 (2025) 142 doi: 10.36922/mi.5075